Joshua Phillips Sells 12,163 Shares of Sera Prognostics, Inc. (NASDAQ:SERA) Stock

Sera Prognostics, Inc. (NASDAQ:SERA) Director Joshua Phillips sold 12,163 shares of the business’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $6.39, for a total value of $77,721.57. Following the completion of the transaction, the director now owns 2 shares of the company’s stock, valued at $12.78. This trade represents a 99.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Sera Prognostics Stock Up 0.6 %

Shares of NASDAQ:SERA opened at $6.37 on Wednesday. The company has a market cap of $215.13 million, a P/E ratio of -6.43 and a beta of 0.86. The business has a fifty day simple moving average of $7.44 and a 200-day simple moving average of $7.31. Sera Prognostics, Inc. has a 52 week low of $4.98 and a 52 week high of $12.35.

Sera Prognostics (NASDAQ:SERA) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.09 million. During the same quarter last year, the firm posted ($0.23) earnings per share. Sell-side analysts expect that Sera Prognostics, Inc. will post -0.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sera Prognostics

Institutional investors have recently bought and sold shares of the stock. Pallas Capital Advisors LLC purchased a new position in Sera Prognostics during the fourth quarter worth approximately $113,000. JPMorgan Chase & Co. grew its stake in shares of Sera Prognostics by 7,357.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 884,867 shares of the company’s stock valued at $6,902,000 after buying an additional 873,002 shares during the period. Barclays PLC increased its holdings in shares of Sera Prognostics by 321.6% during the 3rd quarter. Barclays PLC now owns 39,450 shares of the company’s stock worth $308,000 after buying an additional 30,093 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Sera Prognostics by 8.9% in the 3rd quarter. Geode Capital Management LLC now owns 586,837 shares of the company’s stock worth $4,578,000 after buying an additional 47,969 shares during the period. Finally, Jane Street Group LLC raised its position in shares of Sera Prognostics by 24.8% in the 3rd quarter. Jane Street Group LLC now owns 14,225 shares of the company’s stock worth $111,000 after buying an additional 2,826 shares during the period. 54.64% of the stock is currently owned by hedge funds and other institutional investors.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.